BEDFORD, Ohio, July 16 Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin(R) by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to treat several types of infections caused by susceptible bacteria.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
"In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product which represents Bedford's entry into the cephalosporin market. This continues to demonstrate our commitment to providing a broad based portfolio of products," said David Gaugh, Vice President and General Manager of Bedford Laboratories.
Bedford Laboratories will supply Ceftriaxone for Injection USP as a sterile crystalline powder in glass vials in the following presentations: Single-dose vials containing either 250mg, 500mg, 1g, or 2g equivalent of ceftriaxone packaged in cartons containing 10 vials and a pharmacy bulk vial containing the equivalent of 10g ceftriaxone packaged in cartons containing 1 vial.
Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com.
Rocephin(R) is a registered trademark of Hoffmann-La Roche, Inc.
SOURCE Ben Venue Laboratories, Inc.